FAS Wealth Partners Inc. Buys 2,993 Shares of Edwards Lifesciences Co. (NYSE:EW)

FAS Wealth Partners Inc. lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 14.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,244 shares of the medical research company’s stock after purchasing an additional 2,993 shares during the quarter. FAS Wealth Partners Inc.’s holdings in Edwards Lifesciences were worth $1,849,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Advisors Asset Management Inc. increased its holdings in Edwards Lifesciences by 0.3% during the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock worth $5,127,000 after acquiring an additional 117 shares during the period. Apollon Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 1.0% in the first quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock worth $1,033,000 after purchasing an additional 119 shares during the period. Geller Advisors LLC raised its position in shares of Edwards Lifesciences by 6.5% in the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock worth $231,000 after buying an additional 120 shares in the last quarter. Legacy Wealth Asset Management LLC boosted its stake in Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares during the period. Finally, KCM Investment Advisors LLC grew its position in Edwards Lifesciences by 2.7% during the first quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock worth $635,000 after buying an additional 142 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $72.98, for a total value of $2,141,963.00. Following the sale, the director now directly owns 4,486 shares in the company, valued at approximately $327,388.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Donald E. Bobo, Jr. sold 10,000 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $75.67, for a total value of $756,700.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at approximately $2,989,192.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $72.98, for a total transaction of $2,141,963.00. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at $327,388.28. The disclosure for this sale can be found here. Insiders have sold a total of 189,604 shares of company stock worth $16,022,982 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.1 %

Shares of EW opened at $94.30 on Wednesday. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a market cap of $56.76 billion, a P/E ratio of 41.00, a P/E/G ratio of 4.67 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The company’s fifty day simple moving average is $87.13 and its 200-day simple moving average is $76.46.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 earnings per share. As a group, analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Royal Bank of Canada increased their price target on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target on the stock in a research report on Friday, February 2nd. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Citigroup cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Monday, December 11th. Finally, Mizuho upped their target price on Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $88.80.

View Our Latest Research Report on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.